Semalytix GmbH. (11/24/20). "Press Release: Corporate Vice President of Bayer Pharmaceuticals Becomes Advisor to Semalytix". Bielefeld.

	Organisation	Semalytix GmbH
	Organisation 2	Bayer Pharmaceuticals Corporation
	Group	Bayer (Group)
	Product	AI-based clinical research
	Product 2	drug development
	Person	Jaskolski, Janik (Semalytix 201505– Managing Director + Co-Founder)

Semalytix announced today that Frank Misselwitz, Corporate Vice President of Bayer Pharmaceuticals, is supporting the company in the role of an advisor.

“I am extremely proud to announce today that Frank Misselwitz, Corporate VP of Bayer Pharmaceuticals, will support Semalytix in an advisor role to further our mission to make Patient Centricity a true Northstar KPI in drug development.” says Janik Jaskolski, CEO and co-founder of Semalytix.

Frank Misselwitz brings extensive experience in clinical trial execution and drug development to the company, and will provide strategic guidance to the creation of AI technology that uncovers unknown patient needs to generate the deepest possible understanding of how humans suffer from disease. The company’s ultimate goal is to generate patient experience insights on a greater scale and with more ease for new therapies and to improve the quality of care for billions: one disease at a time.

contact: Jannis Johannmeier
phone: +49(0) 172 5270504
email: press@semalytix.com
web: semalytix.com

Record changed: 2022-02-05